|1.||Gebru, Elias: 2 articles (06/2011 - 07/2009)|
|2.||Park, Seung-Chun: 2 articles (06/2011 - 07/2009)|
|3.||Dudhatra, G B: 1 article (01/2013)|
|4.||Awale, M M: 1 article (01/2013)|
|5.||Mody, S K: 1 article (01/2013)|
|6.||Kumar, Avinash: 1 article (01/2013)|
|7.||Patel, H B: 1 article (01/2013)|
|8.||Kamani, D R: 1 article (01/2013)|
|9.||Chauhan, B N: 1 article (01/2013)|
|10.||Tohamy, M A: 1 article (10/2011)|
01/01/2002 - "The accumulation of orbifloxacin in diseased skin may contribute to the efficacy of this compound for the treatment of bacterial skin infections."
08/01/2004 - "The objective of the study was to evaluate the in vitro activity of orbifloxacin against Staphylococcus intermedius strains isolated in France from canine skin and ear infections. "
08/01/2004 - "In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections."
10/01/2006 - "Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs."
|2.||Bacterial Infections (Bacterial Infection)
01/01/2013 - "Orbifloxacin could be useful for the treatment of bacterial infections in sheep that are sensitive to this drug."
06/01/2006 - "This dose is suggested for further studies on the clinical efficacy of orbifloxacin for treatment of susceptible bacterial infections in the horse."
07/01/2009 - "Therefore, a higher dose of orbifloxacin would be worthy of consideration for treatment of certain bacterial infections in dogs."
|3.||Body Weight (Weight, Body)
10/01/2011 - "In conclusion, 5 mg kg⁻¹ body weight of orbifloxacin administered as a single dose once daily could be useful in the treatment of disease caused by Pasteurella multocida pathogen in ducks."
06/01/2011 - "The objective of this study was to analyze the relationship between pharmacokinetic parameters and body weight (W) for orbifloxacin using reported pharmacokinetic data. "
01/01/2013 - "Single-dose pharmacokinetics of orbifloxacin (2.5mg/kg body weight) were determined in clinically normal female Patanwadi sheep (n=6) following intravenous and intramuscular administration. "
10/01/2011 - "The pharmacokinetic aspects of orbifloxacin were studied in both healthy and naturally diseased ducks after a single intravenous and intramuscular dose of 5 mg kg⁻¹ body weight. "
07/01/2009 - "The pharmacokinetics (PK) and pharmacodynamics (PD) of orbifloxacin were studied in beagle dogs after intravenous (i.v.) and intramuscular (i.m.) administration at a dose of 2.5 mg/kg body weight. "
10/01/2006 - "Under the conditions of this study, orbifloxacin was an effective, safe, and convenient antibiotic for the treatment of superficial and deep staphylococcal pyoderma in dogs."
08/01/2004 - "Orbifloxacin was tested at different concentrations for killing rate against five isolates obtained from pyoderma cases and against a reference strain (Staphylococcus aureus ATCC 29213). "
01/01/2002 - "After dosing on Day 0 and after five to seven daily treatments, dogs with pyoderma had significantly higher mean orbifloxacin skin:plasma ratios (1.40 and 1.44, respectively) than did clinically normal dogs (0.81 and 0.96, respectively). "
01/01/2002 - "Dogs with pyoderma had significantly higher mean skin concentrations of orbifloxacin within 3 hours of administration (Day 0: 7.80 +/- 3.40 mcg/g, Days 4 to 6: 9.47 +/- 6.23 mcg/g) than did dogs with normal skin (Day 0: 3.85 +/- 1.08 mcg/g, Days 4 to 6: 5.43 +/- 1.02 mcg/g). "
01/01/2002 - "Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma."
|5.||Poultry Diseases (Poultry Disease)